A phase 2 clinical trial with bleselumab, a humanized anti-CD40 monoclonal antibody that neutralizes the circulating pathogenic CD40 autoantibodies in FSGS patients, is underway to prevent the recurrence of disease [National Clinical Trial (NCT) number NCT02921789]. Here, CD40 is linked to focal segmental glomerulosclerosis.